| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.003 | 1 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | -0.0047 | 1 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.0034 | 1 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.0023 | 1 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.0022 | 1 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.0028 | 1 |